AbCellera announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ...

Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against ...

AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in ...

APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

In the context of AD, OX40, a costimulatory receptor present on activated T cells, supports the function of inflammatory T cells, exacerbating skin dysfunction. Researchers from Astria Therapeutics ...

Including patients who used topical rescue medication, almost half of patients treated with rocatinlimab met the 75% response criteria compared with 16% of placebo-treated patients. Additionally ...

“We are very excited about the potential for the OX40 mechanism. With the goal of creating the overall best OX40 program, we intentionally have designed STAR-0310 to capitalize on the learnings ...

“We are very excited about the potential for the OX40 mechanism. With the goal of creating the overall best OX40 program, we intentionally have designed STAR-0310 to capitalize on the learnings of ...

This commentary will focus on the emergence of OX40 inhibitors for AD. According to Sadrolashrafi et al, the OX40-OX40 ligand (OX40L) pathway is a crucial modulator of the adaptive immune response.